Business News • PR NewsWire • Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug darolutamide. The submission, which was initiated in December 2018, is...

View More : https://www.prnewswire.com:443/news-releases/bayer-completes-rolling-submission-of-new-drug-application-to-us-food-and-d...

Releted News by prnewswire

Boeing and Bamboo Airways Announce Order for 10 787 Dreamliners

Three in a row: Openlink wins Stevie Award for outstanding customer service

SQM Reports Earnings for the Twelve Months Ended December 31, 2018

U.S. News & World Report Premieres Leaders Talk

Chemical industry M&A expected to face challenges, but remain robust amid global uncertainty: Deloitte Global report